July 17, 2026

On Friday, July 10th, 2026, the FDA issued a proposed rule that, if finalized, will impact pharmaceutical manufacturing for the United States drug market. The rule is intended to strengthen innovation in the pharmaceutical sector while reducing administrative bloat and supply chain blind spots. 

The rule is intended to fix two separate problems. Distributed manufacturers operating under a hub-and-spoke model, in which a central quality oversight hub coordinates multiple equivalent manufacturing units, currently have to register each unit separately, a practice the FDA has determined to be an unnecessary administrative burden. Separately, some foreign establishments that manufacture drugs or drug components, such as active pharmaceutical ingredients, solely for distribution to other foreign establishments, are not currently required to register with the FDA, leaving a gap in the agency's visibility into upstream supply chains. 

Under the proposed rule, distributed manufacturing establishments could register as a single establishment rather than registering each unit separately. Units could be added, relocated, or removed through a streamlined update process, and companies would be required to notify the FDA in advance of any unit relocation, closing what the agency described as a gap in its real-time oversight. The distributed manufacturing framework traces to the FRAME initiative CDER started in 2019, and this specific rule followed a 2022 discussion paper, more than 25 industry comments, and a public workshop. 

A facility only qualifies for this streamlined registration if it's tied to an approved application (NDA, ANDA, NADA, ANADA, or BLA) that already describes a decentralized manufacturing strategy, and if it underwent a preapproval inspection covering each drug profile class it makes. It's not available to just any multi-site operation. The rule explicitly does not cover arrangements in which separate companies, such as different contract manufacturers, each run a site that makes the same drug. It requires one legal entity and one quality system. Relevant for any manufacturer weighing a CMO network structure. A domestic manufacturing unit must register within 5 calendar days of starting commercial operations, and foreign units must register before imports begin. Relocating a mobile unit requires 30 days of advance notice for moves within the US, and 120 days for moves to or within a foreign country. 

The rule would similarly align the FDA's regulations with existing statutory requirements, making clear that foreign establishments manufacturing drugs or drug components for indirect entry into the U.S. supply chain must register with the FDA and report the drugs they produce. The FDA has said this would give the agency a clearer picture of where and how drugs entering the U.S. supply chain are actually made. As of October 2024, nearly 60% of registered drug establishments are foreign, up from about 35% in 2016, which is why this registration gap matters more today than it did the last time this rule was updated. This provision implements Section 2511 of the PREVENT Pandemics Act, signed into law in December 2022. The FDA is updating its own regulations to match a statutory requirement that has already been in effect for years, not introducing new policy. 

The rule doesn't address combination products directly, but it's worth a second look if your operations include such a product. Part 207 registration applies to any establishment that manufactures a drug as defined under the FD&C Act, regardless of which FDA center leads the review of the finished product. That means the facility manufacturing the drug constituent part of a combination product, such as a drug-eluting stent's coating, still falls under drug establishment registration requirements, even when the device carries the primary mode of action and CDRH leads the overall review. Manufacturers producing drug constituent parts should confirm whether their operations fall under this rule, particularly if any part of their supply chain involves indirect foreign distribution, as that is the exact gap this rule seeks to close. 

What This Means If Your Supply Chain Includes Foreign Manufacturers 

A drug made from an unregistered or unlisted foreign component is legally "misbranded" under the FD&C Act 502(o), regardless of whether the US importer knew the supplier was unregistered. The FDA is explicit that a finished-product manufacturer cannot file a registration on a foreign supplier's behalf, unless formally authorized as that supplier's agent, but the finished-product manufacturer still bears the exposure if the supplier isn't properly registered. That means real due diligence obligation flows downstream to whoever imports the finished product. 

Who This Rule Benefits 

Most brands relying on distributed manufacturing or hub-and-spoke registration will manage fewer redundant registrations and lower registration fees. The rule does not quantify benefits to patients, but the value to them is real. Supporting supply chain resiliency and a more agile response during shortages or emergencies can lower costs and ease access issues. 

Foreign establishment registration can benefit patients and consumers directly through greater supply chain visibility and safety oversight. The compliance cost falls on manufacturers, specifically previously unregistered foreign API makers and the US importers who depend on them. The FDA's own estimate puts that industry-wide cost at $533K-$584K annualized. 

Key Takeaways: 

  • Hub-and-spoke consolidation option for distributed manufacturers 
  • Advance notice required for unit relocation 
  • Foreign establishments producing for indirect U.S. entry are now in scope for registration/reporting 
  • The FDA projects reduced registration costs and long-term efficiency gains 
  • Ties to expanded FDA domestic manufacturing push (PreCheck Pilot Program, etc.): https://www.fda.gov/industry/fda-actions-support-and-strengthen-domestic-drug-manufacturing 
  • This rule is still in the proposed stage and is open to public comment. Comments can be made through the Regulations.gov portal until September 11, 2026. Docket No. FDA-2025-N-6075 (RIN 0910-AI94).  

If your operations span multiple manufacturing sites, involve foreign supply relationships, or if you have questions about how evolving FDA registration and listing requirements may affect your business, contact Accorto. 

Sources:

About Accorto Regulatory Solutions

Accorto Regulatory Solutions, LLC is a U.S.-based regulatory consulting firm specializing in FDA regulatory strategy, application development, and compliance support for FDA-regulated products. Accorto works with companies at all stages of growth, from early-stage and startup organizations to established international manufacturers entering or expanding within the U.S. market. With experience across emerging and mature regulatory environments, Accorto helps clients translate regulatory requirements into practical, scalable solutions that support product development, market entry, and long-term compliance.